Free-living amoebae: Difference between revisions
From IDWiki
(typo) |
No edit summary |
||
Line 1: | Line 1: | ||
{| class="wikitable" |
|||
* ''[[Naegleria fowleri]]'' |
|||
! |
|||
⚫ | |||
! ''[[Naegleria fowleri]]'' |
|||
⚫ | |||
! ''[[Balamuthia mandrillaris]]'' |
|||
|- |
|||
! Clinical presentation |
|||
| Primary amebic meningoencephalitis (PAM), with fulminant disease within days and death within 1-2 weeks |
|||
| Granulomatous amebic encephalitis (GAE), with subacute presentations followed by fatal acute stage; may have cutaneous or sinus lesions; amebic keratitis |
|||
| GAE as well, similarly subacute; may have skin lesions |
|||
|- |
|||
! Risk factors |
|||
| Healthy children or young adults with recreational warm fresh-water exposure |
|||
| Immunocompromised people; contact lens wearers, for keratitis |
|||
| Immunocompromised people, but also immunocompetent children and elderly, and Hispanics |
|||
|- |
|||
! Neuroimaging |
|||
| Nonspecific |
|||
| Space-occupying or ring-enhancing lesion (GAE) |
|||
| Space-occupying or ring-enhancing lesion |
|||
|- |
|||
! Diagnosis |
|||
| CSF wet mount or PCR |
|||
| Cysts in brain biopsy, immunostaining or PCR; trophozoites or cysts on corneal scraping |
|||
| Cysts in brain biopsy, immunostaining or PCR |
|||
|- |
|||
! Treatment |
|||
| Intrathecal and intravenous [[amphotericin B]], [[azoles]], [[rifampin]], [[miltefosine]] |
|||
| [[Pentamidine]], [[azoles]], [[flucytosine]], [[sulfadiazine]], [[miltefosine]], [[amikacin]], [[voriconazole]] |
|||
| [[Pentamidine]], [[azithromcin]], [[fluconazole]], [[sulfadiazine]], [[flucytosine]], [[miltefosine]] |
|||
|} |
|||
[[Category:Protozoa]] |
[[Category:Protozoa]] |
Revision as of 02:14, 4 June 2020
Naegleria fowleri | Acanthamoeba species | Balamuthia mandrillaris | |
---|---|---|---|
Clinical presentation | Primary amebic meningoencephalitis (PAM), with fulminant disease within days and death within 1-2 weeks | Granulomatous amebic encephalitis (GAE), with subacute presentations followed by fatal acute stage; may have cutaneous or sinus lesions; amebic keratitis | GAE as well, similarly subacute; may have skin lesions |
Risk factors | Healthy children or young adults with recreational warm fresh-water exposure | Immunocompromised people; contact lens wearers, for keratitis | Immunocompromised people, but also immunocompetent children and elderly, and Hispanics |
Neuroimaging | Nonspecific | Space-occupying or ring-enhancing lesion (GAE) | Space-occupying or ring-enhancing lesion |
Diagnosis | CSF wet mount or PCR | Cysts in brain biopsy, immunostaining or PCR; trophozoites or cysts on corneal scraping | Cysts in brain biopsy, immunostaining or PCR |
Treatment | Intrathecal and intravenous amphotericin B, azoles, rifampin, miltefosine | Pentamidine, azoles, flucytosine, sulfadiazine, miltefosine, amikacin, voriconazole | Pentamidine, azithromcin, fluconazole, sulfadiazine, flucytosine, miltefosine |